Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TRAW files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTraws Pharma reports Q1 2026 financial results in Regulation FD disclosure
Filed May 15, 2026 · Period ending May 15, 2026 · ~1 min read
Key Changes
-
high
Company announced financial results for the quarter ended March 31, 2026 via press release furnished under Regulation FD. Actual figures are in the attached exhibit, not in the 8-K body.
Item 7.01 verify on EDGAR → -
medium
Press release dated May 15, 2026 was attached as Exhibit 99.1. The filing body does not summarize the earnings figures or provide commentary on performance.
Exhibit 99.1 view on EDGAR →
Summary
Traws Pharma disclosed its first quarter 2026 financial results through a press release furnished under Regulation FD rules. The 8-K filing itself contains minimal detail—the actual earnings figures, revenue, and management commentary are in the attached press release (Exhibit 99.1), which was not included in the analyzed text. This is a standard earnings announcement format where companies furnish rather than file results, meaning the information is made public but not subject to certain SEC liability provisions.
Retail investors should obtain the full press release to see Q1 performance metrics, year-over-year comparisons, and any forward guidance. Watch for the company's 10-Q filing in the coming weeks, which will provide audited financials and management discussion that gives fuller context to these headline results.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Traws Pharma filed an 8-K attaching a press release dated May 15, 2026; no material business event disclosed in the filing body.
Added in current filing · verify on EDGAR →
99.1 Press Release, dated May 15, 2026
The 8-K references an attached press release dated May 15, 2026, but the filing body does not disclose the content or subject matter of that release. Without the exhibit text, the materiality and investor impact cannot be determined from this filing alone.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 15, 2026, Traws Pharma, Inc. (the “Company”) issued a press release (the “Earnings Release”) announcing its financial results for the quarter ended March 31, 2026
The company announced its financial results for the first quarter ended March 31, 2026 through a press release. The actual financial figures are contained in Exhibit 99.1, which is furnished but not filed with the SEC under Regulation FD disclosure rules.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 28, 2026 · How we verify